William Ferrar
Richmond, VANPI 1649251935
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,858 of the $6,747 with a category attached, or 86.8%. 31 manufacturers reported payments, led by Amgen at 24.5% of the total. Reporting peaked in 2019 at $2,814 and has fallen 95.0% since, to $140 in 2025.
Across 164 payments — averaging $41.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Paratek Pharmaceuticals, Inc.$800
- AbbVie$700
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$425
- Pfizer$414
- Novo Nordisk$390
- plus $2K from 25 others
What the payments were for
- Consulting fees$80012%
- Food & beverage$5,85887%
- Education$891%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 43 | $1,650 |
| Paratek Pharmaceuticals, Inc. | 1 | $800 |
| AbbVie(2 entities) | 30 | $700 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $425 |
| Pfizer | 12 | $414 |
| Novo Nordisk | 7 | $390 |
| Astellas Pharma US Inc | 5 | $337 |
| Johnson & Johnson | 11 | $311 |
| Esperion Therapeutics, Inc. | 2 | $203 |
| Sanofi-aventis U.S. LLC | 3 | $144 |
| Smith+Nephew | 1 | $140 |
| Lilly USA, LLC | 5 | $138 |
| GSK | 3 | $136 |
| Insightec,inc | 1 | $136 |
| Amarin Pharma, Inc. | 1 | $125 |
| Boehringer Ingelheim | 3 | $121 |
| Dynavax Technologies Corporation | 1 | $117 |
| Biohaven Pharmaceuticals, Inc. | 1 | $94 |
| Edwards Lifesciences | 1 | $90 |
| Abbott | 4 | $58 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Sanofi Pasteur Inc. | 2 | $28 |
| Novartis | 2 | $27 |
| Almatica Pharma LLC | 1 | $23 |
| Sanofi | 1 | $18 |
| Mylan Specialty L.p. | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
| Medtronic | 1 | $13 |
| Merck | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUZYRA$800
- Repatha$358
- EVENITY$354
- AIMOVIG$249
- UBRELVY$239
- MYRBETRIQ$234
- REAL INTELLIGENCE$140
- Exablate$136
- NEXLIZET$125
- NEXLETOL$125
- Vascepa$125
- SOLIQUA 100/33$123
- Ozempic$119
- XARELTO$117
- Heplisav-B$117
- Prolia$115
- Saxenda$112
- VIBERZI$104
- TRELEGY ELLIPTA$104
- ELIQUIS$101
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.